Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, has scheduled a conference call for Tuesday, August 5, 2025, at 5:00 p.m. ET. The call will cover the company's financial performance and corporate updates for Q2 2025, ending June 30, 2025.
Investors can access both the live and replay versions of the webcast through the company's investor relations website. The replay will remain available for three months following the presentation.
Ultragenyx Pharmaceutical (NASDAQ: RARE), un'azienda biofarmaceutica specializzata in trattamenti per malattie genetiche rare e ultra-rare, ha programmato una conference call per martedì 5 agosto 2025 alle 17:00 ET. Durante la chiamata verranno presentati i risultati finanziari e gli aggiornamenti aziendali relativi al secondo trimestre 2025, terminato il 30 giugno 2025.
Gli investitori potranno seguire la diretta e la registrazione della webcast attraverso il sito web dedicato agli investitori della società. La registrazione rimarrà disponibile per tre mesi dopo la presentazione.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una empresa biofarmacéutica especializada en tratamientos para enfermedades genéticas raras y ultra-raras, ha programado una llamada conferencia para el martes 5 de agosto de 2025 a las 5:00 p.m. ET. La llamada abordará el desempeño financiero y las actualizaciones corporativas del segundo trimestre de 2025, que finaliza el 30 de junio de 2025.
Los inversionistas podrán acceder tanto a la transmisión en vivo como a la repetición a través del sitio web de relaciones con inversionistas de la compañía. La repetición estará disponible durante tres meses después de la presentación.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 희귀 및 초희귀 유전 질환 치료에 특화된 바이오제약 회사로, 2025년 8월 5일 화요일 오후 5시(동부시간)에 컨퍼런스 콜을 예정하고 있습니다. 이번 콜에서는 2025년 6월 30일 마감된 2025년 2분기 재무 실적 및 회사 업데이트가 다뤄질 예정입니다.
투자자들은 회사 투자자 관계 웹사이트를 통해 생중계 및 녹화 영상을 시청할 수 있으며, 녹화 영상은 발표 후 3개월간 제공됩니다.
Ultragenyx Pharmaceutical (NASDAQ : RARE), une société biopharmaceutique spécialisée dans les traitements des maladies génétiques rares et ultra-rares, a programmé une conférence téléphonique pour le mardi 5 août 2025 à 17h00 ET. L'appel portera sur les performances financières et les mises à jour corporatives du deuxième trimestre 2025, clos au 30 juin 2025.
Les investisseurs pourront accéder à la fois à la diffusion en direct et à la rediffusion via le site web des relations investisseurs de la société. La rediffusion restera disponible pendant trois mois après la présentation.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf die Behandlung seltener und ultra-seltener genetischer Erkrankungen spezialisiert hat, hat eine Telefonkonferenz für Dienstag, den 5. August 2025, um 17:00 Uhr ET angesetzt. In der Telefonkonferenz werden die Finanzergebnisse und Unternehmensupdates für das zweite Quartal 2025, das am 30. Juni 2025 endet, vorgestellt.
Investoren können sowohl die Live-Übertragung als auch die Aufzeichnung über die Investor-Relations-Website des Unternehmens verfolgen. Die Aufzeichnung wird für drei Monate nach der Präsentation verfügbar sein.
- None.
- None.
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
FAQ
When is Ultragenyx (NASDAQ: RARE) hosting its Q2 2025 earnings call?
How can investors access Ultragenyx's Q2 2025 earnings call?
How long will the replay of Ultragenyx's Q2 2025 earnings call be available?
What period will Ultragenyx's upcoming earnings report cover?
